###### Strengths and limitations of this study

-   This study is the first to examine the seroprevalence of *Entamoeba histolytica* at a voluntary counselling and testing (VCT) centre in Tokyo, where active surveillance for *E. histolytica* infection is lacking, including among asymptomatically infected individuals.

-   This was a cross-sectional study of anonymous clients at a VCT centre. Thus, comparisons are possible of the seroprevalence of *E. histolytica* with other sexually transmitted infections.

-   We could not assess risk behaviour or sexual behaviour and cannot exclude the possibility of selection bias among VCT centre clients.

Introduction {#s1}
============

Amebiasis is an enteric protozoa infection caused by *Entamoeba histolytica*. Up to 80% of *E. histolytica* infections are asymptomatic but persistent; the remainder result in the development of invasive diseases such as colitis and liver abscess.[@R1] Asymptomatically infected individuals represent a risk to the community because they are a source of new infections. Transmission occurs via the oral--faecal route. It has long been believed that amebiasis is only endemic in developing countries where food and water are frequently contaminated with human faeces, or that it occurs among travellers to or immigrants from these countries.[@R1] However, in the previous two decades, it has been reported that cases of amebiasis have been rapidly increasing and have become a re-emerging infectious disease not only in developed countries of East Asia but also in European developed countries.[@R3] Human-to-human transmission occurs via direct sexual contact, such as oral--anal sexual contact and contact among men who have sex with men in these countries.[@R13] Under such circumstances, it is essential to identify individuals who are asymptomatic but chronically infected with *E. histolytica* and who thus represent sources of new infection, for the epidemiologic control of sexually transmitted *E. histolytica* infection. However, little epidemiological data are currently available in Japan, other than that from National Epidemiological Surveillance of Infectious Diseases (NESID), which only reports clinically diagnosed 'symptomatic' cases. Moreover, it is critical to understand the epidemiology of sexually transmitted *E. histolytica* infection before the upcoming Tokyo Olympics in 2020, which could serve as a source of the rapid spread of such neglected communicable diseases.

The aim of this study was to investigate the seroprevalence of *E. histolytica* at a voluntary counselling and testing (VCT) centre in Tokyo, in comparison with the prevalence of other sexually transmitted infections (STIs). In addition, we discuss future strategies for the epidemiologic control of sexually transmitted *E. histolytica* infection.

Methods {#s2}
=======

Setting {#s2-1}
-------

Tokyo, the capital city of Japan, is located on the Pacific on the eastern coast of Honshu, the largest of the four main islands comprising Japan. According to the national surveillance system, the annual number of HIV tests performed and the incidence rates of HIV infection are higher in Tokyo than those of other prefectures.[@R15] The Tokyo Metropolitan Minami Shinjuku Testing---Counselling Center is the largest HIV testing centre in Tokyo, and it is very close to a town in Shinjuku with a large population of men who have sex with men (MSM).[@R16] Because there are more MSM who visit this centre to undergo testing for HIV and other STIs, the incidence rate of HIV infection at this centre is higher than that of other public health centres in Tokyo.[@R17]

Study population, samples and ethics issues {#s2-2}
-------------------------------------------

The design of this study was a cross-sectional study. The total 2083 serum samples used in this study were collected at the Tokyo Metropolitan Minami Shinjuku Testing---Counselling Center where more than 10 000 anonymous clients seek HIV-1 screening tests each year. Collected samples are transferred to the Tokyo Metropolitan Institute of Public Health for laboratory testing, then stored at 4°C. Fourth-generation HIV-1 screening is performed routinely throughout the year. However, in 2 months of the year (eg, June and December in the case of 2017), the Tokyo Metropolitan Government intensifies STI screening, and rapid plasma reagin (RPR) and *Treponema pallidum* hemagglutination (TPHA) tests for syphilis screening are additionally performed for all clients. In addition, urinary sampling and transcription-mediated amplification (TMA) assay testing for *Chlamydia trachomatis* and *Neisseria gonorrhoeae* are performed for clients who are willing to undergo these tests. Therefore, we assessed the seroprevalence of anti-*E. histolytica* antibody using stored serum samples collected in June and December 2017 and compared this with the positivity for other STIs in this study. In this study, there was no selection bias or missing data.

All protocols for this study were conducted in accordance with the Declaration of Helsinki.

Laboratory testing {#s2-3}
------------------

The presence of anti-*E. histolytica* antibody was detected using a commercially available ELISA kit (*E. histolytica* IgG-ELISA; GenWay Biotech, Inc). All procedures were performed according to the manufacturer's instructions. In brief, diluted serum samples (100× dilution in IgG sample diluent) as well as 5 control samples, consisting of 1 substrate blank, 1 negative control, 2 cut-off controls and 1 positive control, were applied to 96-well plates pre-treated with *E. histolytica* antigen and incubated at 37°C for 1 hour. After washing the plates using washing solution, 100 µL of *E. histolytica* Protein A conjugate was added to all wells except the substrate blank and incubated for 30 min in the dark. After a second wash, 3,3',5,5'-tetramethylbenzidine substrate solution was added to all wells. After a 15 min incubation, 100 µL of stop solution was applied to the plates, and absorbance of the specimen was then read at 450/620 nm using a spectrometer.

Statistical analysis {#s2-4}
--------------------

Of the total samples tested in each STI screening test, the proportion of seropositive blood and urine samples is presented with 95% CIs calculated using the Wilson-Brown method. The seroprevalence of *E. histolytica* was compared with that of other STIs using Fisher's exact test. To determine the trend of seropositivity among age groups, we used the χ^2^ test for trend. Statistical significance was defined as a two-sided p value\<0.05. All statistical analyses were conducted using GraphPad Prism (GraphPad Software). Logistic regression analysis for identification of factors influencing *E. histolytica* seropositivity was performed using Stata (StataCorp LLC).

Patient and public involvement {#s2-5}
------------------------------

Patients and public were not involved in the design and conduct of this research.

Results {#s3}
=======

Study population and seroprevalence of *E. histolytica* at a VCT centre in Tokyo {#s3-1}
--------------------------------------------------------------------------------

In total, 2083 samples were analysed. The average age of clients was 35.2 (95% CI: 34.8 to 35.7) years, and 70.8% (1474/2083) were men ([figure 1](#F1){ref-type="fig"}). The overall seropositive rate for *E. histolytica* was 2.64%; this was significantly higher than that for HIV-1 (0.34%) and the comparable level as that for syphilis by RPR (2.11%) ([figure 2A](#F2){ref-type="fig"}). The positive rate of urinary TMA for *C. trachomatis* (4.59%) was higher than that for *E. histolytica*; however, urinary TMA testing for *C. trachomatis* and *N. gonorrhoeae* was only carried out in 69.0% (1437/2083) of clients, that is, those who were willing to undergo TMA testing. These results suggest that *E. histolytica* is a more common STI than HIV-1 in Tokyo and is at a level comparable to that of syphilis infection. Interestingly, all individuals who were seropositive for *E. histolytica* were seronegative for HIV-1 ([figure 2B](#F2){ref-type="fig"}). Furthermore, the seropositive rate for *E. histolytica* was significantly higher among people who were seropositive for syphilis infection (by both RPR and TPHA) than among those who were seronegative for syphilis; no significant differences in *E. histolytica* seropositivity were seen according to TMA positivity for *C. trachomatis*. These results indicate that *E. histolytica* infection is spreading among people at risk for syphilis infection.

![Proportion of clients in each age group among men and women. The average age among female clients was significantly lower than that in male clients (p\<0.001). The proportion of clients aged 29 years or less among female clients was 53.4%, whereas that in male clients was only 29.6%.](bmjopen-2019-031605f01){#F1}

![Seropositivity for *Entamoeba histolytica* and other sexually transmitted infections (STIs) in Tokyo. Serologic testing results (anti-*E. histolytica* antibody, HIV-1, RPR and TPHA) were obtained for 2083 clients of a voluntary counselling and testing centre in June and December 2017. Results of urinary TMA for *Chlamydia trachomatis* and *Neisseria gonorrhoeae* were available for 1437 clients who agreed to testing. All statistics were calculated using Fisher's exact test. (A) The seropositive rate for *E. histolytica* was compared with those of other STIs. (B) Comparison of seropositivity for *E. histolytica*, with and without other STIs. RPR, rapid plasma reagin; TPHA, *Treponema pallidum* hemagglutination; TMA, transcription-mediated amplification.](bmjopen-2019-031605f02){#F2}

Differences in seropositivity by sex and age group {#s3-2}
--------------------------------------------------

Next, we compared positivity for STIs between male and female clients. The seropositive rate for *E. histolytica* was significantly higher in male (3.46%) than in female (0.66%) clients, as seen for syphilis infection (RPR: 2.78% vs 0.49% and TPHA: 9.29% vs 0.82%) ([figure 3A](#F3){ref-type="fig"}). The proportion of urinary TMA results positive for *C. trachomatis* was significantly higher in female (8.77%) than in male (2.65%) clients. However, it is difficult to simply compare the TMA positivity by sex because persistent, asymptomatic *C. trachomatis* infection of the urinary tract occurs more frequently in women.[@R18] Moreover, the age of female clients was significantly lower than that of male clients, and the proportion of clients aged 29 years or less in women was 53.4%, whereas that in men was only 29.6% ([figure 1](#F1){ref-type="fig"}). These results indicate that both male and female clients in this study are at risk for STIs; however, the predominant pathogens might differ between relatively older men (*E. histolytica* and *Treponema pallidum*) and relatively younger women (*C. trachomatis*).

![Positive rate of sexually transmitted infections (STIs) by sex and age group. (A) Positive rate of *Entamoeba histolytica* and other STIs were compared between male (n=1474) and female (n=609) clients using Fisher's exact test. (B) Seropositive rates for *E. histolytica* and RPR, and TMA positivity for *Chlamydia trachomatis* were calculated for clients of different age groups (serum, urine samples): 29 years or younger (752, 503), 30--39 years (666, 453), 40--49 years (443, 315), and 50s or older (222, 167). Correlation between age and positivity was calculated using the χ^2^ test for trend. RPR, rapid plasma reagin test; TPHA, *Treponema pallidum* hemagglutination; TMA, transcription-mediated amplification.](bmjopen-2019-031605f03){#F3}

To determine the trend of *E. histolytica* seropositivity by age, we compared seropositivity for *E. histolytica* in different age groups. Interestingly, the seropositive rates for anti-*E. histolytica* antibody and RPR was highest among clients aged 50 years or older (5.41% and 2.70%, respectively). Moreover, a positive correlation was observed between age and seropositivity for *E. histolytica* ([figure 3B](#F3){ref-type="fig"}). Positive urinary TMA for *C. trachomatis* was highest among clients aged 29 years or younger (8.35%) and showed a negative correlation with age. These results are consistent with national surveillance data, in which diagnosed cases of *Chlamydia* infection have a peak in the 20s,[@R22] whereas the median age of reported cases of amebiasis is relatively high (50 years in men and 40 years in women).[@R5] Considering these findings, *E. histolytica* infection might be more prevalent among relatively older age groups (40 years or more), whereas *Chlamydia* infection is more prevalent in relatively younger populations.

Risk of seropositivity for *E. histolytica* {#s3-3}
-------------------------------------------

Finally, to identify the risk factors of seropositivity for *E. histolytica*, we compared positivity for STIs between clients who were positive and negative for *E. histolytica* ([table 1](#T1){ref-type="table"}). Although there were no statistical differences in the positive rates for HIV-1, *C. trachomatis* or *N. gonorrhoeae*, the positive rates for any STIs were higher in clients who were positive for *E. histolytica* than in *E. histolytica*-negative clients (30.56% vs 10.49%, p=0.0001). Thus, we performed logistic regression analysis using data of client characteristics and the results of STI screening tests. Univariate and multivariate regression analyses revealed that male sex, a history of syphilis infection (by TPHA) and older age were independent risk factors of seropositivity for *E. histolytica* ([table 2](#T2){ref-type="table"}). In particular, age 40 years or older was a high-risk factor of seropositivity for *E. histolytica* (OR 3.31 in people aged less than 40 years, p value\<0.001 by univariate analysis; data not shown). In addition, univariate analysis showed that positive RPR was a high-risk factor for *E. histolytica* seropositivity; however, this was diminished in multivariate analysis owing to the strong association with TPHA positivity. Univariate analysis using preliminary urinary TMA data of 1437 participants showed that positivity for *C. trachomatis* in the urine had no impact on *E. histolytica* seropositivity ([table 2](#T2){ref-type="table"}). We could not include HIV-1 serology and TMA positivity for *N. gonorrhoeae* in urine in the logistic regression analyses because no clients who were HIV-1 seropositive or positive for *N. gonorrhoeae* by TMA were also seropositive for *E. histolytica*.

###### 

Comparison of positive results for other STIs between *Entamoeba histolytica* seropositive and seronegative clients.

                                         *E. histolytica* seropositive   *E. histolytica* seronegative   P value
  -------------------------------------- ------------------------------- ------------------------------- ----------
  Male, % (n)                            92.73% (51/55)                  70.17% (1423/2028)              0.0001
  Age, mean (SD)                         41.6 (12.56)                    35.1 (10.4)                     \<0.0001
  Positive rate, % (n)                                                                                   
   HIV-1                                 0% (0/55)                       0.35% (7/2028)                  \>0.999
   RPR                                   9.09% (5/55)                    1.92% (39/2028)                 0.005
   TPHA                                  29.09% (16/55)                  6.21% (126/2028)                \<0.0001
   Urine *Chlamydia trachomatis* (TMA)   8.33% (3/36)                    4.50% (63/1401)                 0.227
   Urine *Neisseria gonorrhoeae* (TMA)   0% (0/36)                       0.14% (2/1401)                  \>0.999
   Any of the above STIs                 30.56% (11/36)                  10.49% (147/1401)               0.0001

The positive rate of any of the other STIs was calculated only in clients whose blood and urine were tested.

RPR, rapid plasma reagin; STIs, sexually transmitted infections; TMA, transcription-mediated amplification; TPHA, *Treponema pallidum* hemagglutination.

###### 

Impact of individual characteristics of seropositivity for *Entamoeba histolytica*, Tokyo.

  --------------------------------------------------------------------------------------------------------------------------
                                                  Univariate analysis   Multivariate analysis\*                    
  ----------------------------------------------- --------------------- ------------------------- ---------------- ---------
  Sex (male)                                      5.42\                 \<0.001                   3.17\            0.032
                                                  (1.95 to 15.06)                                 (1.10 to 9.07)   

  Older age\                                      1.66\                 \<0.001                   1.49\            0.001
  (by 10-year age groups)                         (1.33 to 2.08)                                  (1.17 to 1.90)   

  HIV-1 positive                                  ND†                                                              

  Syphilis infection                                                                                               

   RPR positive                                   5.1\                  0.006                     1.26\            0.693
                                                  (1.93 to 13.49)                                 (0.41 to 3.89)   

   TPHA positive                                  6.19\                 \<0.001                   4.30\            \<0.001
                                                  (3.37 to 11.39)                                 (2.11 to 8.76)   

  Urine *Chlamydia trachomatis* (TMA) positive‡   1.93\                 0.326                                      
                                                  (0.58 to 6.47)                                                   

  Urine *Neisseria gonorrhoeae* (TMA) positive‡   ND†                                                              
  --------------------------------------------------------------------------------------------------------------------------

\*Multivariate analysis for age and sex, plus factors with p\<0.05 in univariate analysis.

†ORs could not be determined in logistic regression analysis because all clients who were HIV-1 positive and/or positive for gonorrhoea by TMA were *E. histolytica* seronegative.

‡Data of urinary TMA testing available only for 69.0% (1437 of 2083) of total clients.

RPR, rapid plasma reagin; TPHA, *Treponema pallidum* hemagglutination; TMA, transcription-mediated amplification; ND, not determined.

Discussion {#s4}
==========

The most important finding of this study was that the seroprevalence of *E. histolytica* was significantly (7.9 times) higher than that of HIV-1 and it was comparable to that for syphilis (by RPR), indicating that *E. histolytica* is now a potential re-emerging pathogen in our country. Certainly, it is difficult to simply compare seropositivity among these three tests; the HIV-1 screening test continues to be positive for a person's entire life, whereas positivity in RPR and anti-*E. histolytica* antibody tests indicate current or recent infection.[@R21] However, these results strongly indicate that the endemicity of *E. histolytica* in Tokyo is higher than that of HIV-1 and close to the level of syphilis. In contrast to our seroprevalence data, the national surveillance data of Japan from NESID pragmatically show that the annual number of diagnosed cases of amebiasis (1151 in 2016) is not only much lower than that of syphilis (4575 cases), it is also lower than that of HIV-1 (1443 cases).[@R22] Our results suggest that the endemicity of amebiasis in Japan is currently underestimated, thereby remaining a neglected disease in Japan despite frequently reported life-threatening cases of amebiasis.[@R24] Interestingly, in this study, all individuals who were seropositive for *E. histolytica* were HIV-1 negative, whereas regression analysis identified that seropositivity for syphilis by TPHA was an independent risk factor of a positive result for anti-*E. histolytica* antibody. Previous reports have emphasised the high seroprevalence of *E. histolytica* [@R28] and increasing number of amebiasis cases[@R29] among individuals with HIV-1 infection. Although the epidemiological trend of *E. histolytica* among HIV-1-positive individuals could not be assessed in this study owing to the small number of clients who were positive for HIV-1, it should be noted that sexually transmitted *E. histolytica* infection is currently spreading even among HIV-1-negative populations, as we indicated in our earlier hospital-based cross-sectional analysis.[@R32] Currently, screening for *E. histolytica* is not routinely performed at VCT centres in Japan; however, public health interventions should be considered to control sexually transmitted *E. histolytica* infection.

The clinical significance of seropositivity for *E. histolytica* remains unclear and is beyond the scope of this paper. Serologic testing is a sensitive diagnostic method for symptomatic invasive amebiasis; however, positive results are also obtained for recent infections, up to the previous several years.[@R25] However, we had reported earlier that 70.4% of *E. histolytica*-seropositive individuals did not have any amebiasis-related symptoms nor any history of treatment for amebiasis. Interestingly, 20% of such individuals in a Japanese HIV-1 cohort developed symptomatic invasive amebiasis within a 1-year follow-up period.[@R28] In another cross-sectional analysis, we also reported that ulcerative lesions owing to *E. histolytica* in the large intestine are frequently identified (7/18, 38.9%) by colonoscopy among asymptomatic individuals who are *E. histolytica* seropositive, whereas these rarely (1/53, 1.9%) occur among *E. histolytica*-seronegative people.[@R33] Serologic screening for *E. histolytica* at VCT centres, followed by diagnosis of subclinical *E. histolytica* infection by colonoscopy and treatment at a referral hospital, is one possible public health strategy against sexually transmitted *E. histolytica* infection. However, we must assess the utility of serologic testing for the screening of asymptomatic *E. histolytica* in well-designed prospective analyses in the future.

This study has some limitations that should be considered. First, this preliminary investigation was a cross-sectional study of anonymous clients at a VCT centre. We could not assess risk behaviours, including sexual orientation, socioeconomic status, sanitation and dietary habits, with respect to seropositivity for *E. histolytica* owing to a lack of detailed data on the characteristics of clients. Therefore, further intensive epidemiological studies are needed, to assist in developing future intervention approaches for this re-emerging infectious disease. In addition, the study periods were 2 months apart owing to the availability of data for not only HIV-1 but also other STIs (serum tests for syphilis and urine tests for chlamydia and gonorrhoea). We could not exclude the possibility of selection bias of clients, such as those who undergo repeat testing. Second, anti-*E. histolytica* antibody was screened using stored serum. Long periods of storage could lead to lower sensitivity of serologic tests, resulting in underestimation of the seroprevalence of *E. histolytica*. Third, we obtained a considerably lower seropositive rate for *E. histolytica* among female clients (0.66%, 4/609) than that among male clients (3.46%, 51/1474). This probably results from the fact that VCT centres may not be appropriate for identifying female populations at high risk for *E. histolytica* infection; our female clients were relatively younger and had lower seropositive rates in RPR and TPHA tests. More appropriate sampling locations should be identified such as STI clinics that are visited by female commercial sex workers.[@R34]

In conclusion, among clients of a VCT centre in Tokyo, seropositivity for *E. histolytica* was 7.9 times higher than that of HIV-1 and tended to be high among individuals at risk of syphilis infection. Active detection and treatment of asymptomatic cases of *E. histolytica* infection should be considered for the epidemiologic control of sexually transmitted *E. histolytica* infection in Japan.
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